Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C16H14O4 |
| Molecular Weight | 270.28 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC2=C(C=C1)[C@@H]3COC4=CC(O)=CC=C4[C@@H]3O2
InChI
InChIKey=NSRJSISNDPOJOP-BBRMVZONSA-N
InChI=1S/C16H14O4/c1-18-10-3-5-11-13-8-19-14-6-9(17)2-4-12(14)16(13)20-15(11)7-10/h2-7,13,16-17H,8H2,1H3/t13-,16-/m0/s1
| Molecular Formula | C16H14O4 |
| Molecular Weight | 270.28 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Medicarpin, is a pterocarpan-type phytoalexin which is also classified as methoxylated isoflavonoid and is one of the major constituents of dietary legumes. Medicarpin is present in chickpea (Cicer arietinum), peanut (Arachis hypogaea), alfalfa (Medicago sativa), red clover (Trifolium pratense) and in an Indian medicinal plant Butea monosperma. Medicarpin, a legume phytoalexin has excellent oral bioavailability and potent antiproliferative activity against breast cancer and acute myeloid leukemia (AML) cells. Medicarpin also inhibits the oncogenic NF-kB signaling by attenuating the TNF-α-induced nuclear translocation of p65. Medicarpin stimulates osteoblast differentiation likely via estrogen receptor (ER) beta, promotes achievement of peak bone mass. Medicarpin inhibits ER stress-induced apoptosis and promotes osteoblast cell survival by targeting GRP78. Medicarpin was isolated as nematicidal constituent from the extract Taverniera abyssinica A.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: WP254 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25321472 |
|||
Target ID: CHEMBL242 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21333515 |
|||
Target ID: P20029 Gene ID: 14828.0 Gene Symbol: Hspa5 Target Organism: Mus musculus (Mouse) Sources: https://www.ncbi.nlm.nih.gov/pubmed/27316719 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Curative | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Identification of cDNAs encoding pterocarpan reductase involved in isoflavan phytoalexin biosynthesis in Lotus japonicus by EST mining. | 2006-10-16 |
|
| Constituents of the roots of Pueraria lobata inhibit formation of advanced glycation end products (AGEs). | 2006-10 |
|
| Profiling isoflavonoids found in legume root extracts using capillary electrophoresis. | 2002-06 |
|
| Cytotoxic activity of low molecular weight polyphenols against human oral tumor cell lines. | 2000-08-23 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21333515
Rat: 5 mg/kg single dose
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25321472
Myeloid leukemia cells were incubated in culture media supplemented with dimethyl sulfoxide (DMSO) or various concentrations of Medicarpin (5, 10, 20, 50, 100 uM) or TRAIL (1, 2.5, 5, 10, 25 ng) for 48 h. Medicarpin alone significantly reduced Myeloid leukemia cell viability at higher doses and showed sensitization with various doses of TRAIL in all the cell lines at a dose of 20 uM.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:34:29 GMT 2025
by
admin
on
Mon Mar 31 19:34:29 GMT 2025
|
| Record UNII |
6TX086I6IG
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
6TX086I6IG
Created by
admin on Mon Mar 31 19:34:29 GMT 2025 , Edited by admin on Mon Mar 31 19:34:29 GMT 2025
|
PRIMARY | |||
|
MEDICARPIN
Created by
admin on Mon Mar 31 19:34:29 GMT 2025 , Edited by admin on Mon Mar 31 19:34:29 GMT 2025
|
PRIMARY | |||
|
32383-76-9
Created by
admin on Mon Mar 31 19:34:29 GMT 2025 , Edited by admin on Mon Mar 31 19:34:29 GMT 2025
|
PRIMARY | |||
|
C047353
Created by
admin on Mon Mar 31 19:34:29 GMT 2025 , Edited by admin on Mon Mar 31 19:34:29 GMT 2025
|
PRIMARY | |||
|
16114
Created by
admin on Mon Mar 31 19:34:29 GMT 2025 , Edited by admin on Mon Mar 31 19:34:29 GMT 2025
|
PRIMARY | |||
|
350085
Created by
admin on Mon Mar 31 19:34:29 GMT 2025 , Edited by admin on Mon Mar 31 19:34:29 GMT 2025
|
PRIMARY | |||
|
m7130
Created by
admin on Mon Mar 31 19:34:29 GMT 2025 , Edited by admin on Mon Mar 31 19:34:29 GMT 2025
|
PRIMARY | Merck Index | ||
|
DTXSID301026587
Created by
admin on Mon Mar 31 19:34:29 GMT 2025 , Edited by admin on Mon Mar 31 19:34:29 GMT 2025
|
PRIMARY | |||
|
336327
Created by
admin on Mon Mar 31 19:34:29 GMT 2025 , Edited by admin on Mon Mar 31 19:34:29 GMT 2025
|
PRIMARY | |||
|
6714
Created by
admin on Mon Mar 31 19:34:29 GMT 2025 , Edited by admin on Mon Mar 31 19:34:29 GMT 2025
|
PRIMARY | |||
|
100
Created by
admin on Mon Mar 31 19:34:29 GMT 2025 , Edited by admin on Mon Mar 31 19:34:29 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |